Advances in PET imaging of brain tumors: A referring physician's perspective

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 617-623

  Petrirena, Gregorio J ^a   Goldman, Serge ^b   Delattre, Jean Yves ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ERASME HOSPITAL   (Belgium)

Author keywords

brain tumor; methionine; novel tracers; PET

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTA FLUOROPROPYL)ACETAMIDE; 3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; FLUOROETHYLTYROSINE F18; IRINOTECAN; METHIONINE C 11; TRACER; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; BRAIN DAMAGE; BRAIN METASTASIS; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; CLINICAL PRACTICE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; HYPOXIA; ISOTOPE LABELING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN ATTITUDE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR BIOPSY;

BRAIN NEOPLASMS; CARBON RADIOISOTOPES; DIDEOXYNUCLEOSIDES; FLUORINE RADIOISOTOPES; GLIOBLASTOMA; GLIOMA; HUMANS; METHIONINE; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 80054106755     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834aa752     Document Type: Review

References (79)

1. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24:3282-3292. (Pubitemid 46622068)
2. Michalski MH, Chen X. Molecular imaging in cancer treatment. Eur J NuclMed Mol Imaging 2011; 38:358-377.
3. Rowe C. Neuroscience. J Nucl Med 2010; 51:31N-37N.
4. Patton DD. Introduction to clinical decision making. Semin Nucl Med 2010; 40:319-326.
5. Collins JM. Functional imaging in phase I studies: decorations or decision making? J Clin Oncol 2003; 21:2807-2809. (Pubitemid 46621827)
6. Schellingerhout D, Gelovani J. Clinical trials in a molecular world. Neuroimag Clin N Am 2006; 16:681-694. (Pubitemid 44828760)
7. van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neurooncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011; 12:583-593.
8. Reardon DA, Galanis E, DeGroot JF, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 2011; 13:353-361.
9. Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimag Clin N Am 2009; 19:625-646.
10. Klä sner BD, Krause BJ, Beer AJ, Drzezga A. PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed. Expert Rev Anticancer Ther 2010; 10:609-613.
11. Singhal T, Narayanan TK, Jain V, et al. 11C-L-Methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008; 10:1-18.
12. Langen KJ, Hamacher K, Weckesser M, et al. O-(2-[18F]fluoroethyl)- LTyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006; 33:287-294.
13. Vallabhajosula S. 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 2007; 37:400-419. (Pubitemid 47505221)
14. Okubo S, Zhen H-N, Kawai N, et al. Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J Neurooncol 2010; 99:217-225.
15. Okita Y, Kinoshita M, Goto T, et al. 11C-Methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. NeuroImage 2010; 49:2977-2982.
16. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008; 49:129S-148S. (Pubitemid 351948041)
17. Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging 2010; 37:S86-S103.
18. Bading JR, Shields AF. Imaging of cells proliferation: status and prospects. J Nucl Med 2008; 49:64S-80S. (Pubitemid 351948037)
19. Cohen A, Shirvan A, Levin G, et al. From the Gla domain to a novel smallmolecule detector of apoptosis. Cell Res 2009; 19:625-637.
20. Henze M, Schuhmacher J, Hipp P, et al. PET Imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 2001; 42:1053-1056. (Pubitemid 32595304)
21. Horky LL, Treves ST. PET and SPECT in brain tumors and epilepsy. Neurosurg Clin N Am 2011; 22:169-184.
22. Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F]fluoroethyl)-L-Tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000; 27:542-549. (Pubitemid 30262620)
23. Becherer A, Karanikas G, Szabó M, et al. Brain tumour imaging with PET: a comparison between [18F] fluorodopa and [11C] methionine. Eur J Nucl Med Mol Imaging 2003; 30:1561-1567. (Pubitemid 37356125)
24. Pichler R, Dunzinger A, Wurm G, et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 2010; 37:1521-1528.
25. Goldman S, Pirotte BJ. Brain tumors. Methods Mol Biol 2011; 727:291-315.
26. Galldiks N, Kracht LW, Berthold F, et al. [11C]-L-Methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol 2010; 96:231-239.
27. Pauleit D, Stoffels G, Bachofner A, et al. Comparison of 18F-FET and 18FFDG PET in brain tumors. Nucl Med Biol 2009; 36:779-787.
28. Salber D, Stoffels G, Oros-Peusquens AM, et al. Comparison of O-(2-18Ffluoroethyl)-L-tyrosine and L-3H-methionine uptake in cerebral hematomas. J Nucl Med 2010; 51:790-797.
29. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008; 62:753-766.
30. Pirotte BJ, LevivierM, Goldman S, et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 2009; 64:471-481.
31. Floeth FW, Sabel M, Ewelt C, et al. Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging 2011; 38:731-741.
32. Lau EW, Drummond KJ, Ware RE, et al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci 2010; 17:43-49.
33. Tripathi M, Sharma R, D'Souza M, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 2009; 34:878-883.
34. Jacobs AH, Kracht LW, Gossmann A, et al. Imaging in neurooncology. NeuroRx 2005; 2:333-347. (Pubitemid 40471440)
35. Plotkin M, Blechschmidt C, Auf G, et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of noncontrast-enhancing gliomas. Eur Radiol 2010; 20:2496-2502.
36. WeberMA, Henze M, Tutenberg J, et al. Biopsy targeting gliomas. Do functional imaging techniques identify similar target areas? Invest Radiol 2010; 45:755-768.
37. Herholz K, Hö lzer T, Bauer B, et al. 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998; 50:1316-1322. (Pubitemid 28240345)
38. Fueger BJ, Czernin J, Cloughesy T, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 2010; 51:1532-1538.
39. Pö pperl G, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007; 34:1933-1942.
40. Schiepers C, Chen W, Cloughesy T, et al. 18F-FDOPA kinetics in brain tumors. J Nucl Med 2007; 48:1651-1661.
41. Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic 18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 2011; 13:307-316.
42. Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neurooncol 2009; 95:87-93.
43. Ullrich RT, Kracht L, Brunn A, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 2009; 50:1962-1968.
44. Dhermain FG, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 2010; 9:906-920.
45. Piroth MD, Pinkawa M, Holy R, et al. Prognostic value of early 18F-fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011; 80:176-184.
46. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963-1972.
47. Matsusue E, Fink JR, Rockhill JK, et al. Distinction between glioma progression and postradiation change by combined physiologic MR imaging. Neuroradiology 2010; 52:297-306.
48. Galban CJ, Chenevert TL, Meyer CR, et al. Prospective analysis of parametric MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res 2011 Jul 12 [Epub ahead of print].
49. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 2009; 9:381-390.
50. Pistollato F, Abbadi S, Rampazzo E, et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010; 28:851-862.
51. Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Molecular imaging of hypoxia. J Nucl Med 2011; 52:165-168.
52. Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 2009; 69:4502-4509.
53. Spence AM, Muzi M, Swanson KR, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008; 14:2623-2630.
54. Koch CJ, Scheuermann JS, Divgi C, et al. Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl MedMol Imaging 2010; 37:2048-2059.
55. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62. (Pubitemid 40093472)
56. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011; 6:2.
57. Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics 2009; 6:447-457.
58. Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 2009; 11:861-870.
59. Weber WA. Monitoring tumor response to therapy with 18F-FLT PET. J Nucl Med 2010; 51:841-844.
60. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007; 25:4714-4721. (Pubitemid 350086472)
61. Schiepers C, Dahlbom M, Chen W, et al. Kinetics of 30-deoxy-30-18F- fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med 2010; 51:720-727.
62. Spence AM, Muzi M, Link JM, et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 30-deoxy-30-[18F] fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol 2009; 11:343-355.
63. Reshef A, Shirvan A, Akselrod-Ballin A, et al. small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med 2010; 51:837-840.
64. Hö glund J, Shirvan A, Antoni G, et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med 2011; 52:720-725.
65. Shirvan A, Reshef A, Allen A, et al. Apoptosis imaging with PET-18F-ML-10 for early assessment of response of brain metastases to radiotherapy. J Nuc Med. SNM Meeting Abstracts 2009; 50 (Suppl 2):453.
66. Kamar FG, Posner JB. Brain metastases. Semin Neurol 2010; 30:217-235.
67. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010; 9:135.
68. Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother Oncol 2010; 96:325-327.
69. Nyuyki F, Plotkin M, Graf R, et al. Potential impact of 68Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging 2010; 37:310-318.
70. Vees H, Senthamizhchelvan S, Miralbell R, et al. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging 2009; 36:182-193.
71. Tang BN, Van Simaeys G, Devriendt D, et al. Three-dimensional Gaussian model to define brain metastasis limits on (11)C-methionine PET. Radiother Oncol 2008; 89:270-277.
72. Bentzen SM, Gregoire V. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol 2011; 21:101-110.
73. Wahl RL, Herman JM, Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol 2011; 21:88-100.
74. Koch CJ, Shuman AL, Jenkins WT, et al. The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake. Int J Radiat Biol 2009; 85:1137-1147.
75. Walter F, Cloughesy T, Lai A, et al. Impact of F-DOPA PET/CT imaging on the management of patients with brain tumors: the referring physician's. J Nucl Med. SNM Meeting Abstracts 2010; 51 (Suppl. 2):1801.
76. Yamane T, Sakamoto S, Senda M. Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging 2010; 37:685-690.
77. Pichler BJ, Kolb A, Nä gele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010; 51:333-336.
78. Boss A, Bisdas S, Kolb A, et al.Hybrid PET/MRI of intracranialmasses: initial experiences and comparison to PET/CT. J Nucl Med 2010; 51:1198-1205.
79. Wistuba II, Gelovani JG, Jacoby JJ, et al. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 2011; 8:135-141.